Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture
Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected at $720–$760 million, well below prior expectations. 2025 profitability was buoyed by favorable mix, cost controls, and a one-time $60 million order, but these drivers are not expected to recur. Competitive pressure on naloxone and uneven government procurement drive margin compression and revenue unpredictability, with adjusted EBITDA guided down to $135-$155 million in 2026.
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Emergent Biosolutions (EBS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?
Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript
Emergent BioSolutions Inc. ( EBS ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Frank Vargo Joseph Papa - CEO, President & Director Richard Lindahl - Executive VP, CFO & Treasurer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $1.37 per share a year ago.
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
Emergent BioSolutions delivered a strong Q2 2025, beating its own guidance and showing major improvements in margins. EBS has a sound turnaround strategy that is showing signs of success. The company has some competitive advantages to maintain and grow market share.
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Joseph C. Papa - CEO, President & Director Richard S.
